Prediction of Delayed Cognitive Impairment in Cardiac Arrest Survivors With Good Neurological Outcomes
NCT ID: NCT05830422
Last Updated: 2024-02-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ENROLLING_BY_INVITATION
40 participants
OBSERVATIONAL
2023-11-01
2027-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main questions it aims to answer are:
* Can we identify abnormal areas in the brains of patients with delayed cognitive impairment using Brain MRI or positron emission tomography (PET) imaging?
* Is it possible to predict delayed cognitive impairment using biomarkers?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Early and Objective Assessment of Neurological Prognosis in Cardiac Arrest Patients
NCT06387225
Neurological Outcomes After In-Hospital Cardiac Arrest
NCT03006484
Early DiaGnosis of Anoxic Brain Injury for Resuscitated Patients
NCT03806660
Heart Evaluation of Acute Ischemic Stroke With Reperfusion Therapy
NCT06882577
Brain Heart InterActioNs in Cardiac Arrest. Ancillary Study of the HEAVENwARd Trial
NCT06327334
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Blood samples were collected through venous puncture at days 10-14, 3 months, and 6 months after ROSC, and the obtained blood was drawn into an serum separating tube (SST) bottle without anticoagulants, then centrifuged within 60 minutes after collection (at 3,000rpm for at least 10 minutes) and divided into tubes. The processed tubes were stored at -70°C.
* The storage period of the samples is 5 years from the date of collection, and they are stored in a coded manner for anonymization.
* The Human Neurology 4-ples A 2.0 Assay Kit (including neurofilament light chain, Tau protein, ubiquitin carboxyl terminal esterase L1 protein \[UCHL1\], and glial fibrillary acidic protein antibody) was analyzed using the single molecule protein detection (SIMOA) analysis machine, and neuron-specific enolase (NSE) in the blood was analyzed together as a reference point to assess the usefulness of each biomarker.
3. Through the Seoul Neuropsychological Screening Battery (SNSB), attention, language and related functions, visuospatial function, memory, frontal lobe and executive function, and other related functions can be assessed. The test is conducted by a specialist clinical psychologist for 1 hour and 30 minutes to 2 hours, and the results are analyzed by Professor Oh Eung-Seok, a neurologist. The presence of cognitive impairment is assessed by conducting tests at 10-14 days, 3 months, and 6 months after ROSC for out-of-hospital cardiac arrest patients with CPC 1-2 points who have passed 10-14 days since ROSC. In addition, through detailed item analysis of the SNSB, functional abnormalities and affected areas (such as the frontal lobe, parietal lobe, temporal lobe, and occipital lobe) are analyzed.
4. We consulted with the departments of radiology, nuclear medicine, and neurology professors to establish the optimal fluorine-18 (18F) fluorodeoxyglucose (FDG) PET \& MRI examination protocol. The first MRI examination was performed 72-96 hours after ROSC, as recommended by international treatment guidelines for predicting neurological prognosis. The first \[18F\]-FDG PET examination was performed at 10-14 days after ROSC, as it may result in false positives if performed too early in cardiac arrest patients. A minimum of 10 days is recommended before performing the examination. If cognitive impairment is observed in the SNSB examination at 3 months after ROSC, a second \[18F\]-FDG PET \& MRI examination is performed. If the cognitive function is normal at 6 months, the examination is performed regardless of cognitive impairment.
5. Prediction and analysis of delayed cognitive impairment and cause analysis in out-of-hospital cardiac arrest patients with good neurological outcomes
6. Delayed cognitive impairment is defined based on the SNSB results, and is defined as the positive group. For biomarkers, differences between the positive and negative groups are determined at each time point, and the predictive power and cut-off values are determined using area under the receiver operating characteristics curve. For images, the functional or anatomical differences between the two groups are compared.
7. Predictive power analysis Through SNSB, the patient's cognitive impairment and the time point of recognition are measured, and the level of biomarkers tested prior to the recognition of impairment is checked to analyze the predictive power. Therefore, the time points for predictive power analysis are 10-14 days, 3 months, and 6 months after ROSC. The first and second \[18F\]-FDG PET \& MRI findings are analyzed to identify differences between the cognitive impairment group and the normal group. Using multiple modes combining clinical data, biomarkers, \[18F\]-FDG PET, MRI, etc., a predictive model for delayed cognitive impairment is developed.
8. Cause analysis Investigate the impairment findings and location using the continuously measured SNSB test values. Analyze the first and second \[18F\]-FDG PET and MRI findings to investigate the functional or anatomical abnormalities occurring in patients with cognitive impairment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Good neurological outcome
Patients who showed good neurological outcomes with CPC scores of 1-2 at discharge
nothing
Follow-up observation was conducted without any intervention in an outpatient setting.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
nothing
Follow-up observation was conducted without any intervention in an outpatient setting.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with Glasgow Coma Scale (GCS) less than 8 points after spontaneous circulation recovery
* Patients who are 18 years old or older
* Patients who underwent targeted temperature management (TTM)
* Patients who showed good neurological outcomes with CPC 1-2 points after evaluating the prognosis on days 10-14 after ROSC
Exclusion Criteria
* cardiac arrest cause is trauma
* Patients who have not undergone targeted temperature management
* Patients treated with extracorporeal membrane oxygenation (ECMO)
* Patients who were not able to undergo SNSB testing
* Patients who could not be followed up until 6 months after ROSC
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chungnam National University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jung Soo Park, MD.Phd
Role: STUDY_CHAIR
(35015) Chungnam National University Hospital, 282 Munhwa-ro, Jung-gu, Daejeon
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
박정수
Daejeon, Seo-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Cronberg T, Greer DM, Lilja G, Moulaert V, Swindell P, Rossetti AO. Brain injury after cardiac arrest: from prognostication of comatose patients to rehabilitation. Lancet Neurol. 2020 Jul;19(7):611-622. doi: 10.1016/S1474-4422(20)30117-4.
Bronnick K, Evald L, Duez CHV, Grejs AM, Jeppesen AN, Kirkegaard H, Nielsen JF, Soreide E. Biomarker prognostication of cognitive impairment may be feasible even in out-of hospital cardical arrest survivors with good neurological outcome. Resuscitation. 2021 May;162:396-402. doi: 10.1016/j.resuscitation.2021.02.025. Epub 2021 Feb 22.
Moulaert VR, Verbunt JA, van Heugten CM, Wade DT. Cognitive impairments in survivors of out-of-hospital cardiac arrest: a systematic review. Resuscitation. 2009 Mar;80(3):297-305. doi: 10.1016/j.resuscitation.2008.10.034. Epub 2008 Dec 30.
Elliott VJ, Rodgers DL, Brett SJ. Systematic review of quality of life and other patient-centred outcomes after cardiac arrest survival. Resuscitation. 2011 Mar;82(3):247-56. doi: 10.1016/j.resuscitation.2010.10.030. Epub 2011 Jan 8.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CNUH 2022-10-059-004
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.